Opportunity Information: Apply for PAR 13 113
Apply for PAR 13 113
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.351 Research Infrastructure Programs.
- This funding opportunity was created on Jul 3, 2013 and posted on Feb 11, 2013.
- Applicants must submit their applications by Jul 3, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses County governments Public housing authorities/Indian housing authorities Special district governments Public and State controlled institutions of higher education Private institutions of higher education State governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal governments (Federally recognized) Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are noteligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-13-113, titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)," supports Resource-Related Research Project Grant (R24) applications that aim to strengthen the preclinical foundations needed for stem cell based regenerative medicine. At its core, the program is designed to make stem cell therapies more translatable to humans by improving how animal systems are used to study stem cell biology, evaluate safety and effectiveness, and model human disease in ways that better predict clinical outcomes. Rather than focusing on a single disease area, the emphasis is on building and refining broadly useful resources, tools, and animal models that the wider research community can use to accelerate progress toward regenerative treatments.
The announcement highlights three major scientific priorities. First, it encourages comparative studies of animal and human stem cells, with the goal of identifying which animal species and stem cell types best mirror human cell behavior in relevant biological contexts. This includes generating data that help researchers choose model systems that are more predictive and informative for particular therapeutic questions, such as engraftment, differentiation, immune interactions, durability of repair, and functional recovery. Second, it promotes the development of new technologies that improve stem cell characterization and transplantation in animal models. This can include improved methods to track transplanted cells, measure their fate over time, assess functional integration, and more rigorously evaluate mechanisms of action and adverse outcomes. Third, it supports improvement of existing animal disease models and creation of new ones specifically tailored for stem cell based therapeutic testing, so that disease features, progression, and clinically relevant endpoints align more closely with human conditions and the realities of how therapies would be delivered.
Administratively, this is a discretionary grant program under the NIH, listed under CFDA 93.351 (Research Infrastructure Programs). The funding instrument is a grant, and the activity category is health. There is no cost sharing or matching requirement, which typically means applicants are not required to provide non-federal funds as a condition of receiving an award. The opportunity was posted on February 11, 2013, with an original closing date of May 7, 2016, but it also lists a current closing date of July 3, 2013, and an archive date of August 3, 2013, indicating the opportunity is now archived and no longer accepting applications under that announcement cycle.
Eligibility is broad across U.S.-based organizations and governments, reflecting the resource-building nature of an R24 mechanism. Eligible applicants include public and private institutions of higher education; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (including small businesses and other than small businesses); and a range of governmental entities such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly includes various categories often referenced in NIH eligibility language, such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Foreign institutions are not eligible, and foreign components are not allowed, including non-U.S. components of U.S. organizations, consistent with the FOA statement that non-domestic entities and foreign components (as defined by NIH policy) cannot participate in that capacity.
Overall, the opportunity is best understood as an NIH effort to reduce the gap between promising stem cell findings and reliable, reproducible therapeutic progress by investing in better animal stem cell knowledge, better measurement and transplantation tools, and disease models that more faithfully represent the clinical problems regenerative medicine is trying to solve. The full archived announcement was provided through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-113.html, and technical access issues were routed to the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.
FAQs: NIH PAR-13-113 - Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)
What is the funding opportunity PAR-13-113?
PAR-13-113 is an NIH funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)." It supports Resource-Related Research Project Grant (R24) applications aimed at strengthening the preclinical foundations needed for stem cell based regenerative medicine.
What is the main purpose of this program?
The purpose is to make stem cell therapies more translatable to humans by improving how animal systems are used to study stem cell biology, evaluate safety and effectiveness, and model human disease in ways that better predict clinical outcomes.
What type of grant mechanism does this opportunity use?
This opportunity uses the NIH Resource-Related Research Project Grant (R24) mechanism.
Is this opportunity focused on a single disease area?
No. The emphasis is on building and refining broadly useful resources, tools, and animal models that the wider research community can use to accelerate progress toward regenerative treatments, rather than focusing on a single disease area.
What kinds of projects does PAR-13-113 aim to support?
The announcement emphasizes projects that improve and expand animal models and enabling resources for stem cell based regenerative medicine, including efforts that improve predictive value for clinical translation and support more rigorous evaluation of safety, effectiveness, and mechanisms.
What are the major scientific priorities highlighted in the announcement?
The FOA highlights three major priorities: (1) comparative studies of animal and human stem cells to determine which models best mirror human biology, (2) development of new technologies to improve stem cell characterization and transplantation studies in animal models, and (3) improvement of existing animal disease models and creation of new ones tailored for stem cell therapeutic testing with clinically relevant endpoints.
What does "comparative studies of animal and human stem cells" mean in this context?
It refers to generating data that help identify which animal species and stem cell types most closely reflect human stem cell behavior in relevant biological contexts, so researchers can select model systems that are more predictive for particular therapeutic questions.
What therapeutic questions are specifically mentioned as examples for choosing better model systems?
The announcement mentions examples such as engraftment, differentiation, immune interactions, durability of repair, and functional recovery as areas where improved model selection and comparative data can increase predictive value for human outcomes.
What kinds of technology development does the FOA encourage?
It encourages technologies that improve stem cell characterization and transplantation studies in animal models, including improved methods to track transplanted cells, measure cell fate over time, assess functional integration, and more rigorously evaluate mechanisms of action and adverse outcomes.
What does the FOA mean by improving or creating animal disease models tailored for stem cell testing?
It means refining existing models or building new ones so disease features, progression, and endpoints are more closely aligned with human conditions and with the realities of how stem cell based therapies would be delivered and evaluated clinically.
What agency is offering this grant opportunity?
This is a discretionary grant program under the National Institutes of Health (NIH).
What is the CFDA number listed for this program?
The announcement lists CFDA 93.351 (Research Infrastructure Programs).
What is the funding instrument and activity category?
The funding instrument is a grant, and the activity category is health.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement, meaning applicants typically are not required to provide non-federal funds as a condition of receiving an award.
Is PAR-13-113 still accepting applications?
No. The opportunity is archived. While it lists dates including an original closing date of May 7, 2016, it also lists a current closing date of July 3, 2013 and an archive date of August 3, 2013, indicating it is no longer accepting applications under that announcement cycle.
When was the opportunity posted?
The opportunity was posted on February 11, 2013.
What dates are provided for closing and archiving?
The information provided includes an original closing date of May 7, 2016, a current closing date of July 3, 2013, and an archive date of August 3, 2013.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizations and governmental entities. Eligible applicants include public and private institutions of higher education; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (including small businesses and other than small businesses); and governmental entities such as state, county, and city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are specific institution types (like HBCUs or Tribal Colleges) included in the eligible applicant categories?
Yes. The FOA explicitly includes categories commonly referenced in NIH eligibility language, including Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. The eligible applicant categories explicitly include faith-based or community-based organizations.
Are U.S. territories or possessions included as eligible applicants?
Yes. The FOA includes U.S. territories or possessions among eligible applicant categories.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible under this FOA.
Are foreign components allowed as part of an application?
No. Foreign components are not allowed, including non-U.S. components of U.S. organizations, consistent with the FOA statement that non-domestic entities and foreign components (as defined by NIH policy) cannot participate in that capacity.
Where can the full announcement be found?
The full archived announcement is available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-113.html.
Who is referenced for technical access issues related to the announcement?
Technical access issues were routed to the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.
How should this opportunity be understood at a high level?
It is an NIH effort to reduce the gap between promising stem cell findings and reliable, reproducible therapeutic progress by investing in better animal stem cell knowledge, better measurement and transplantation tools, and disease models that more faithfully represent the clinical problems regenerative medicine is trying to solve.
Browse more opportunities from the same category: Health
Next opportunity: Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R01)
Previous opportunity: Woody Biomass Utilization Grant
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 113
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 113) also looked into and applied for these:
| Funding Opportunity |
|---|
| Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R21) Apply for PAR 13 115 Funding Number: PAR 13 115 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enhancing Opioid Treatment Program Patient Continuity of Care through Data Interoperability Apply for TI 13 010 Funding Number: TI 13 010 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $50,000 |
| NINDS Institutional Center Core Grants to Support Neuroscience Research (P30) Apply for PAR 13 116 Funding Number: PAR 13 116 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| STD Surveillance Network (SSuN) Apply for CDC RFA PS13 1306 Funding Number: CDC RFA PS13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,100,000 |
| Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care (R34) Apply for RFA MH 14 141 Funding Number: RFA MH 14 141 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care (R01) Apply for RFA MH 14 140 Funding Number: RFA MH 14 140 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Electronic Data Methods (EDM) Forum Second Phase (U18) Apply for RFA HS 13 004 Funding Number: RFA HS 13 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Rapid Hepatitis C Virus Screening and Referral Apply for TI 13 009 Funding Number: TI 13 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $40,000 |
| Offender Reentry Program Apply for TI 13 007 Funding Number: TI 13 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $430,000 |
| Rural Health Information Technology (HIT) Workforce Program Apply for HRSA 13 251 Funding Number: HRSA 13 251 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity and Associated Risk Factors and Promote School Health Apply for CDC RFA DP13 1305 Funding Number: CDC RFA DP13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $745,000 |
| Research on Alcohol and HIV/AIDS (R03) Apply for PA 13 120 Funding Number: PA 13 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol and HIV/AIDS (R01) Apply for PA 13 121 Funding Number: PA 13 121 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol and HIV/AIDS (R21) Apply for PA 13 122 Funding Number: PA 13 122 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Limited Competition Extramural Research Facilities Improvement Program (C06) Apply for RFA OD 13 003 Funding Number: RFA OD 13 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional and International Differences in Health and Longevity at Older Ages (R03) Apply for PA 13 123 Funding Number: PA 13 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional and International Differences in Health and Longevity at Older Ages (R21) Apply for PA 13 124 Funding Number: PA 13 124 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Regional and International Differences in Health and Longevity at Older Ages (R01) Apply for PA 13 125 Funding Number: PA 13 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Stroke Trials Network Regional Coordinating Stroke Centers (U10) Apply for RFA NS 13 011 Funding Number: RFA NS 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Stroke Trials Network National Clinical Coordinating Center (U01) Apply for RFA NS 13 012 Funding Number: RFA NS 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 113", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.